Study examines cost-effectiveness of Gardasil

A new study in the New England Journal of Medicine questions the cost-effectiveness of Gardasil in older women, saying that the payback is reduced by their increased exposure to the virus that causes cervical cancer. But the team of researchers from Harvard School of Public Health also confirmed that the vaccine is cost-effective among pre-adolescent girls because of their reduced exposure to the virus. Merck, which makes the vaccine and markets it around the world, quickly disputed the study, saying that its own economic models indicate that the vaccine provides a real payback when used for women.

The discussion over cost-effectiveness in the older age bracket is critical for Merck, which wants to expand the use of the cervical cancer vaccine. That expanded use is key to the company's efforts to gain more revenue from the vaccine. It's also an important discussion for GlaxoSmithKline, which has been commercializing Cervarix in various markets and working to gain an FDA approval.

--read the report in the Wall Street Journal

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

With COVID vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies with leading vaccines.

The U.K. became the first Western country to authorize a COVID-19 vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.